Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

January 1, 2021

Study Completion Date

January 1, 2021

Conditions

High Risk Superficial Upper Urinary Tract Transitional Cell CarcinomaEndoscopic Surgical ProcedureTransitional Epithelial Cells

Interventions

DRUG

MK-3475 and BCG

combination treatment with MK-3475 and BCG after endoscopic ablation

Trial Locations (1)

Shaheen Alanee, MD, MPH, MBA, Detroit

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Shaheen Alanee

OTHER